Cyclosporine and sirolimus interaction in a kidney transplant patient

Transplantation Proceedings

Volumn 37, Issue 5, 2005, Pages 2317-2319

  Dabrowska Zamojcin E ^a   Pawlik, A ^a   Domanski L ^a   Rozanski J ^a   Drozdzik M ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ATORVASTATIN; CEFUROXIME; CYCLOSPORIN A; CYTOCHROME P450 3A4; FUROSEMIDE; GLYCOPROTEIN P; LANSOPRAZOLE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PREDNISONE; RAPAMYCIN;

ADULT; ARTICLE; CASE REPORT; DIARRHEA; FEMALE; GENETIC POLYMORPHISM; GRAFT VERSUS HOST REACTION; HOSPITAL ADMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL;

ADULT; BINDING, COMPETITIVE; CYCLOSPORINE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; P-GLYCOPROTEIN; SIROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 21844468947     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2005.03.094     Document Type: Article

References (12)

1. J.M. Kovarik, P. Burtin Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmunediseases Expert Opin Emerg Drugs 8 2003 47
2. S. Bai, S.M. Stepkowski, B.D. Kahan Metabolic interaction between cyclosporine and sirolimus Transplantation 77 2004 1507
3. P. Kelly, B.D. Kahan Review metabolism of immunosuppressant drugs Curr Drug Metab 3 2002 275
4. A. Lo, G.J. Burckart P-glycoprotein and drug therapy in organ transplantation J Clin Pharmacol 39 1999 995
5. T. Kronbach, V. Fischer, U.A. Meyer Cyclosporine metabolism in human liver identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs Clin Pharmacol Ther 43 1988 630
6. M. Sattler, F.P. Guengerich, C.H. Yun Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat Drug Metab Dispos 20 1992 753
7. K. Mahalati, B.D. Kahan Clinical pharmacokinetics of sirolimus Clin Pharmacokin 40 2001 573
8. D.S. Miller, G. Fricker, J. Dreve P-glycoprotein-mediated transport of a fluorescent rapamycin derivate in renal proximal tubule J Pharmacol Exp Ther 282 1997 449
9. R. Arceci, Stieglitz, B. Bierer Immunosuppressants FK 506 and Rapamycin function as reversal agents of the multidrug resistance phenotype Blood 80 1992 1528
10. K.L. Napoli, M.E. Wang, S.M. Stepkowski Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat evidence for pharmacokinetic Ther Drug Monit 20 1998 123
11. B. Kaplan, H.U. Meier-Kriesche, K.L. Napoli The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent Clin Pharmacol Ther 63 1998 48
12. W. Engelen, G.A. Verpooten, M. Van der Planken Four cases of red blood cell aplasia in association with the use of mycophenolate mofetil in renal transplant patients Clin Nephrol 60 2003 119